# Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

> **NCT00787384** · PHASE2 · COMPLETED · sponsor: **Northern Italy Leukemia Group** · enrollment: 25 (actual)

## Conditions studied

- Hypereosinophilic Syndrome
- Chronic Eosinophilic Leukemia
- Chronic Idiopathic Hypereosinophilia

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00787384
- **Lead sponsor:** Northern Italy Leukemia Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2010-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00787384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00787384, "Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00787384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*